Alivus Life Sciences Signs Shareholders Agreement With IQGen-X Pharma

Market snapshot: Alivus Life Sciences Limited has executed a Shareholders' Agreement with IQGen-X Pharma Private Limited and its continuing existing shareholders. This agreement formalizes governance terms following Alivus's acquisition of a majority controlling stake in IQGen-X Pharma.

Data Snapshot

• Alivus Life Sciences executed a Shareholders' Agreement with IQGen-X Pharma Private Limited and continuing shareholders on November 11, 2026.
• Alivus Life Sciences approved the acquisition of a 76% equity stake in IQGen-X Pharma for a total consideration of ₹9.12 crore.
• IQGen-X Pharma recorded a total turnover of ₹3.48 crore for the financial year ended March 31, 2026.

What's Changed

• Transitioned from the initial share purchase agreement to a fully executed Shareholders' Agreement defining corporate governance terms with founding shareholders.

Key Takeaways

• Execution of the Shareholders' Agreement completes the formalization of Alivus's 76% stake acquisition in IQGen-X Pharma.
• Continuing existing shareholders Dr. Mandar Kodgule and Dr. Yogita Kodgule will maintain management participation under mutually agreed rights and obligations.
• Integrates IQGen-X's formulation development platform in oral solids, injectables, and ophthalmics into Alivus's core active pharmaceutical ingredient business.

SAHI Perspective

The formal execution of the Shareholders' Agreement establishes key governance structures while ensuring founder retention. Combining IQGen-X's formulation development capabilities with Alivus's API manufacturing platform enhances value extraction across contract development and manufacturing operations.

Market Implications

Strengthens Alivus Life Sciences' positioning as an end-to-end CDMO partner, allowing the company to capture higher-margin formulation development contracts alongside core API supplies.

Trading Signals

Market Bias: Bullish

The finalized Shareholders' Agreement secures governance controls for Alivus's 76% stake acquisition of IQGen-X Pharma for ₹9.12 crore, expanding analytical capabilities in a business generating ₹3.48 crore in annual revenue.

Overweight: Pharmaceutical APIs & CDMO

Trigger Factors:

• Commercial integration of IQGen-X analytical platforms
• New CDMO contract announcements in complex injectables

Time Horizon: Medium-term (3-12 months)

Industry Context

Active pharmaceutical ingredient manufacturers in India are expanding vertically into finished dosage formulation development and CDMO services to offer integrated global solutions.

Key Risks to Watch

• Execution risk in integrating formulation CDMO operations with core API business
• Regulatory timelines for complex injectable and ophthalmic filings

Recent Developments

In August 2026, Alivus Life Sciences approved acquiring a 76% stake in IQGen-X Pharma for ₹9.12 crore to expand formulation development capability. In November 2026, promoter entity Nirma Limited sold 28.46 lakh shares of Alivus Life Sciences worth ₹390 crore via a market block deal.

Closing Insight

Finalizing governance arrangements with founding shareholders safeguards operational continuity while empowering Alivus to offer integrated formulation and API platforms.

High Performance Trading with SAHI.